Reimbursement Premiums Down In Japan
This article was originally published in PharmAsia News
Executive Summary
Both the volume and size of premiums given to drugs during the reimbursement process in Japan are down in 2012, according to analysis by L.E.K. Consulting, and it might not be a one-year anomaly.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.